<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240719141228&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240719141228&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 19 Jul 2024 18:12:28 +0000</lastbuilddate>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Pulmonary artery pressure-guided heart failure care: the setting matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae441. doi: 10.1093/eurheartj/ehae441. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39027970</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae441>10.1093/eurheartj/ehae441</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027970</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefan Störk</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pressure-guided heart failure care: the setting matters</dc:title>
<dc:identifier>pmid:39027970</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae441</dc:identifier>
</item>
<item>
<title>Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027969/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae424. doi: 10.1093/eurheartj/ehae424. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39027969</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae424>10.1093/eurheartj/ehae424</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027969</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Aschermann</dc:creator>
<dc:creator>Jean Jacques Monsuez</dc:creator>
<dc:creator>Goksel Cinier</dc:creator>
<dc:creator>Editors Network of the National Societies of Cardiology Journals, European Society of Cardiology</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals</dc:title>
<dc:identifier>pmid:39027969</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae424</dc:identifier>
</item>
<item>
<title>Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae445. doi: 10.1093/eurheartj/ehae445. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39027965</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae445>10.1093/eurheartj/ehae445</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027965</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Alfonso Jurado-Román</dc:creator>
<dc:creator>Pilar Agudo-Quílez</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance</dc:title>
<dc:identifier>pmid:39027965</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae445</dc:identifier>
</item>
<item>
<title>Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027946/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae398. doi: 10.1093/eurheartj/ehae398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the efficacy and safety of catheter-based LAAC, largely compared with vitamin K antagonists. LAA device iterations, advances in pre- and peri-procedural imaging, and implantation techniques continue to increase the efficacy and safety of LAAC. More data about efficacy and safety of LAAC have been collected, and several randomized clinical trials are currently underway to compare LAAC with best medical care (including non-vitamin K antagonist oral anticoagulants) in different clinical settings. Surgical LAAC in patients with AF undergoing cardiac surgery reduced the risk of stroke on background of anticoagulation therapy in the LAAOS III study. In this review, we describe the rapidly evolving field of LAAC and discuss recent clinical data, ongoing studies, open questions, and current limitations of LAAC.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027946/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39027946</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae398>10.1093/eurheartj/ehae398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027946</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives</dc:title>
<dc:identifier>pmid:39027946</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae398</dc:identifier>
</item>
<item>
<title>A New linc(-RNA) Between NFAT/MEF2 and Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39024397/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 19;135(3):450-452. doi: 10.1161/CIRCRESAHA.124.324794. Epub 2024 Jul 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39024397/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39024397</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324794>10.1161/CIRCRESAHA.124.324794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39024397</guid>
<pubDate>Thu, 18 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chen Gao</dc:creator>
<dc:creator>Yibin Wang</dc:creator>
<dc:date>2024-07-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>A New linc(-RNA) Between NFAT/MEF2 and Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:39024397</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324794</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39024395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 19;135(3):414-415. doi: 10.1161/RES.0000000000000683. Epub 2024 Jul 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39024395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39024395</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000683>10.1161/RES.0000000000000683</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39024395</guid>
<pubDate>Thu, 18 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39024395</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000683</dc:identifier>
</item>
<item>
<title>Dietary patterns to promote cardiometabolic health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39020052/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the risk of cardiovascular events. Furthermore, low sodium intake can be particularly beneficial for patients with hypertension. Carbohydrate restriction, with an emphasis on including high-quality carbohydrates and limiting refined starches and foods and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 17. doi: 10.1038/s41569-024-01061-7. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the risk of cardiovascular events. Furthermore, low sodium intake can be particularly beneficial for patients with hypertension. Carbohydrate restriction, with an emphasis on including high-quality carbohydrates and limiting refined starches and foods and beverages with added sugars, can promote weight loss and cardiometabolic benefits in the short term, compared with higher carbohydrate intake. Evidence is lacking for sustained, long-term effects of low carbohydrate and very low carbohydrate intake on cardiometabolic risk and cardiovascular outcomes. Time-restricted eating, in the context of an overall healthy dietary pattern, can promote cardiometabolic health by aligning food intake with the circadian rhythm, although its effect on hard clinical outcomes remains to be proven. Although there is no one dietary pattern that is appropriate for all patients, engaging in shared decision-making with patients, utilizing behaviour-change principles and engaging members of the health-care team, such as registered dietitian nutritionists, can lead to substantial improvement in the lifestyle and overall health trajectory of a patient. Emphasizing the similarities, rather than differences, of recommended dietary patterns, which include an emphasis on vegetables, fruits, legumes, nuts, whole grains and minimally processed protein foods, such as fatty fish or plant-based proteins, can simplify the process for both patients and clinicians alike.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39020052/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39020052</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01061-7>10.1038/s41569-024-01061-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39020052</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Robert J Ostfeld</dc:creator>
<dc:creator>Carol F Kirkpatrick</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Dietary patterns to promote cardiometabolic health</dc:title>
<dc:identifier>pmid:39020052</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01061-7</dc:identifier>
</item>
<item>
<title>Septal Ablation to Treat Subaortic Dynamic Obstruction Following Transcatheter Aortic Valve Implantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>Dynamic obstruction of the left ventricle is an unusual complication that can occur after aortic valve replacement. It is important to be aware of this pathology as it requires different management than normal complications and can rapidly lead to death. We present a case of successful resolution following transcatheter aortic valve implantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):411-415. doi: 10.1016/j.jacc.2024.05.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dynamic obstruction of the left ventricle is an unusual complication that can occur after aortic valve replacement. It is important to be aware of this pathology as it requires different management than normal complications and can rapidly lead to death. We present a case of successful resolution following transcatheter aortic valve implantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019535</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.032>10.1016/j.jacc.2024.05.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019535</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lidia María Carrillo Mora</dc:creator>
<dc:creator>José Javier Tercero Fajardo</dc:creator>
<dc:creator>Diana Milena Cruz Sepúlveda</dc:creator>
<dc:creator>Juan Ramón Gimeno Blanes</dc:creator>
<dc:creator>Juan García De Lara</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Septal Ablation to Treat Subaortic Dynamic Obstruction Following Transcatheter Aortic Valve Implantation</dc:title>
<dc:identifier>pmid:39019535</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.032</dc:identifier>
</item>
<item>
<title>Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019534/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):408-410. doi: 10.1016/j.jacc.2024.05.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019534/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019534</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.028>10.1016/j.jacc.2024.05.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019534</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucas L Marinho</dc:creator>
<dc:creator>Brendan M Everett</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Frank L J Visseren</dc:creator>
<dc:creator>Jean G MacFadyen</dc:creator>
<dc:creator>Elaine Zaharris</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Raul D Santos</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Jean-Charles Fruchart</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Aruna Das Pradhan</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT</dc:title>
<dc:identifier>pmid:39019534</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.028</dc:identifier>
</item>
<item>
<title>Sutureless Valves, a "Wireless" Option for Patients With Aortic Valve Disease: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019533/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>Transcatheter technologies triggered the recent revision of the guidelines that progressively widened the indications for the treatment of aortic stenosis. On the surgical realm, a technology avoiding the need for sutures to anchor the prosthesis to the aortic annulus has been developed with the aim to reduce the duration of cardiopulmonary bypass and simplify the process of valve implantation. In addition to a transcatheter aortic valve replacement (TAVR)-like stent that exerts a radial force,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):382-407. doi: 10.1016/j.jacc.2024.05.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcatheter technologies triggered the recent revision of the guidelines that progressively widened the indications for the treatment of aortic stenosis. On the surgical realm, a technology avoiding the need for sutures to anchor the prosthesis to the aortic annulus has been developed with the aim to reduce the duration of cardiopulmonary bypass and simplify the process of valve implantation. In addition to a transcatheter aortic valve replacement (TAVR)-like stent that exerts a radial force, these so-called "rapid deployment valves" or "sutureless valves" for aortic valve replacement also have cuffs to improve sealing and reduce the risk of paravalvular leak. Despite promising, the actual advantage of sutureless valves over traditional surgical procedures (surgical aortic valve replacement) or TAVR is still debated. This review summarizes the current comparative evidence reporting outcomes of "sutureless valves" for aortic valve replacement to TAVR and surgical aortic valve replacement in the treatment of aortic valve stenosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019533/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019533</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.031>10.1016/j.jacc.2024.05.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019533</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Cristiano Spadaccio</dc:creator>
<dc:creator>Antonio Nenna</dc:creator>
<dc:creator>Angelo Pisani</dc:creator>
<dc:creator>Grzegorz Laskawski</dc:creator>
<dc:creator>Francesco Nappi</dc:creator>
<dc:creator>Marc R Moon</dc:creator>
<dc:creator>Fausto Biancari</dc:creator>
<dc:creator>Arminder S Jassar</dc:creator>
<dc:creator>Kevin L Greason</dc:creator>
<dc:creator>Malakh L Shrestha</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>David Rose</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sutureless Valves, a "Wireless" Option for Patients With Aortic Valve Disease: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39019533</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.031</dc:identifier>
</item>
<item>
<title>Reluctance: The Ongoing Reality of Intravascular Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):379-381. doi: 10.1016/j.jacc.2024.05.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019532</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.026>10.1016/j.jacc.2024.05.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019532</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Luis Gruberg</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reluctance: The Ongoing Reality of Intravascular Imaging</dc:title>
<dc:identifier>pmid:39019532</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.026</dc:identifier>
</item>
<item>
<title>Anticoagulants in Subclinical Atrial Fibrillation: Beginning to Define the Treatment Paradigm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019531/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):365-367. doi: 10.1016/j.jacc.2024.05.015. Epub 2024 May 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019531/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019531</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.015>10.1016/j.jacc.2024.05.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019531</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sachin J Shah</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anticoagulants in Subclinical Atrial Fibrillation: Beginning to Define the Treatment Paradigm</dc:title>
<dc:identifier>pmid:39019531</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.015</dc:identifier>
</item>
<item>
<title>Apixaban vs Aspirin According to CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA(2)DS(2)-VASc score >;4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA(2)DS(2)-VASc score &lt;4. A substantial intermediate group (CHA(2)DS(2)-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):354-364. doi: 10.1016/j.jacc.2024.05.002. Epub 2024 May 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To help inform decision making, the authors evaluated the efficacy and safety of apixaban according to baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a subgroup analysis according to baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score and assessed both the relative and absolute differences in stroke/SE and major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were &lt;4 in 1,578 (39.4%) patients, 4 in 1,349 (33.6%), and >;4 in 1,085 (27.0%). For patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc >;4, the rate of stroke was 0.98%/year with apixaban and 2.25%/year with aspirin; compared with aspirin, apixaban prevented 1.28 (95% CI: 0.43-2.12) strokes/SE per 100 patient-years and caused 0.68 (95% CI: -0.23 to 1.57) major bleeds. For CHA<sub>2</sub>DS<sub>2</sub>-VASc &lt;4, the stroke/SE rate was 0.85%/year with apixaban and 0.97%/year with aspirin. Apixaban prevented 0.12 (95% CI: -0.38 to 0.62) strokes/SE per 100 patient-years and caused 0.33 (95% CI: -0.27 to 0.92) major bleeds. For patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc =4, apixaban prevented 0.32 (95% CI: -0.16 to 0.79) strokes/SE per 100 patient-years and caused 0.28 (95% CI: -0.30 to 0.86) major bleeds.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA<sub>2</sub>DS<sub>2</sub>-VASc score >;4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score &lt;4. A substantial intermediate group (CHA<sub>2</sub>DS<sub>2</sub>-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; NCT01938248).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019530</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.002>10.1016/j.jacc.2024.05.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019530</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>William F McIntyre</dc:creator>
<dc:creator>Marco Alings</dc:creator>
<dc:creator>Thenmozhi Mani</dc:creator>
<dc:creator>Chinthanie Ramasundarahettige</dc:creator>
<dc:creator>Lena Rivard</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>David H Birnie</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Guy Amit</dc:creator>
<dc:creator>Peter Leong-Sit</dc:creator>
<dc:creator>Claus Rinne</dc:creator>
<dc:creator>Gabor Z Duray</dc:creator>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>Stefan H Hohnloser</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:creator>Juan Benezet-Mazuecos</dc:creator>
<dc:creator>Jens Cosedis Nielsen</dc:creator>
<dc:creator>Christian Sticherling</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Cecilia Linde</dc:creator>
<dc:creator>Joseph Kautzner</dc:creator>
<dc:creator>Philippe Mabo</dc:creator>
<dc:creator>Georges H Mairesse</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Apixaban vs Aspirin According to CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA</dc:title>
<dc:identifier>pmid:39019530</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.002</dc:identifier>
</item>
<item>
<title>Does REVIVED Complete You?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019529/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):351-353. doi: 10.1016/j.jacc.2024.05.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019529/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019529</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.024>10.1016/j.jacc.2024.05.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019529</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Fiyyaz Ahmed-Jushuf</dc:creator>
<dc:creator>Shayna Chotai</dc:creator>
<dc:creator>Rasha K Al-Lamee</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Does REVIVED Complete You?</dc:title>
<dc:identifier>pmid:39019529</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.024</dc:identifier>
</item>
<item>
<title>Early Uptitration of GDMT Is Associated With More Successful Decongestion and Better Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019528/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):337-339. doi: 10.1016/j.jacc.2024.05.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019528/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019528</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.030>10.1016/j.jacc.2024.05.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019528</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Biykem Bozkurt</dc:creator>
<dc:creator>Ajith Nair</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Uptitration of GDMT Is Associated With More Successful Decongestion and Better Outcomes</dc:title>
<dc:identifier>pmid:39019528</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.030</dc:identifier>
</item>
<item>
<title>Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019527/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In STRONG-HF, intensive uptitration of neurohormonal blockade was associated with more efficient and sustained decongestion at day 90 and a lower risk of the primary endpoint.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):323-336. doi: 10.1016/j.jacc.2024.04.055.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Comprehensive uptitration of neurohormonal blockade targets fundamental mechanisms underlying development of congestion and may be an additional approach for decongestion after acute heart failure (AHF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This hypothesis was tested in the STRONG-HF (Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro-Brain Natriuretic Peptide Testing of Heart Failure Therapies) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In STRONG-HF, patients with AHF were randomized to the high-intensity care (HIC) arm with fast up-titration of neurohormonal blockade or to usual care (UC). Successful decongestion was defined as an absence of peripheral edema, pulmonary rales, and jugular venous pressure &lt;6 cm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, the same proportion of patients in both arms had successful decongestion (HIC 48% vs UC 46%; P = 0.52). At day 90, higher proportion of patients in the HIC arm (75%) experienced successful decongestion vs the UC arm (68%) (P = 0.0001). Each separate component of the congestion score was significantly better in the HIC arm (all, P &lt; 0.05). Additional markers of decongestion also favored the HIC: weight reduction (adjusted mean difference: -1.36 kg; 95% CI: -1.92 to -0.79 kg), N-terminal pro-B-type natriuretic peptide level, and lower orthopnea severity (all, P &lt; 0.001). More effective decongestion was achieved despite a lower mean daily dose of loop diuretics at day 90 in the HIC arm. Among patients with successful decongestion at baseline, those in the HIC arm had a significantly better chance of sustaining decongestion at day 90. Successful decongestion in all subjects was associated with a lower risk of 180-day HF readmission or all-cause death (HR: 0.40; 95% CI: 0.27-0.59; P &lt; 0.0001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In STRONG-HF, intensive uptitration of neurohormonal blockade was associated with more efficient and sustained decongestion at day 90 and a lower risk of the primary endpoint.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019527/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019527</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.055>10.1016/j.jacc.2024.04.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019527</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jan Biegus</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:creator>Beth Davison</dc:creator>
<dc:creator>Gad Cotter</dc:creator>
<dc:creator>Christopher Edwards</dc:creator>
<dc:creator>Jelena Čelutkienė</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:creator>Alain Cohen-Solal</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Maria Novosadova</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Marianna Adamo</dc:creator>
<dc:creator>Mattia Arrigo</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Jozine M Ter Maaten</dc:creator>
<dc:creator>Benjamin Deniau</dc:creator>
<dc:creator>Marianela Barros</dc:creator>
<dc:creator>Kamilė Čerlinskaitė-Bajorė</dc:creator>
<dc:creator>Albertino Damasceno</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Etienne Gayat</dc:creator>
<dc:creator>Antoine Kimmoun</dc:creator>
<dc:creator>Peter S Pang</dc:creator>
<dc:creator>Matteo Pagnesi</dc:creator>
<dc:creator>Hadiza Saidu</dc:creator>
<dc:creator>Koji Takagi</dc:creator>
<dc:creator>Daniela Tomasoni</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF</dc:title>
<dc:identifier>pmid:39019527</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.055</dc:identifier>
</item>
<item>
<title>From periphery to center stage: 50 years of advancements in innate immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 16:S0092-8674(24)00770-0. doi: 10.1016/j.cell.2024.07.010. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39019038</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.010>10.1016/j.cell.2024.07.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019038</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Susan Carpenter</dc:creator>
<dc:creator>Luke A J O'Neill</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>From periphery to center stage: 50 years of advancements in innate immunity</dc:title>
<dc:identifier>pmid:39019038</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.010</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39018080/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, higher plasma lipoprotein(a) concentrations were associated with faster rates of hemodynamic progression in patients with aortic stenosis. Lowering plasma lipoprotein(a) concentrations warrants further investigation in the prevention and treatment of aortic stenosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 17:e241882. doi: 10.1001/jamacardio.2024.1882. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: There are currently no pharmacological treatments available to slow hemodynamic progression of aortic stenosis. Plasma lipoprotein(a) concentrations predict incident aortic stenosis but its association with hemodynamic progression is controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the association between plasma lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTINGS AND PARTICIPANTS: The study included patients with aortic stenosis from 5 longitudinal clinical studies conducted from March 2001 to March 2023 in Canada and the UK. Of 757 total patients, data on plasma lipoprotein(a) concentrations and rates of hemodynamic progression assessed by echocardiography were available for 710, who were included in this analysis. Data were analyzed from March 2023 to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Cohort-specific plasma lipoprotein(a) concentration tertiles.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Hemodynamic aortic stenosis progression on echocardiography as assessed by annualized change in peak aortic jet velocity, mean transvalvular gradient, and aortic valve area.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the included patients, 497 (70%) were male and 213 (30%) were female. The mean (SD) age was 65.2 (13.1) years. Patients in the top lipoprotein(a) tertile demonstrated 41% (estimate, 1.41; 95% CI, 1.13-1.75) faster progression of peak aortic jet velocity and 57% (estimate, 1.57; 95% CI, 1.18-2.10) faster progression of mean transvalvular gradient than patients in the bottom tertile. There was no evidence of heterogeneity across the individual cohorts. Progression of aortic valve area was comparable between groups (estimate, 1.23; 95% CI, 0.71-2.12). Similar results were observed when plasma lipoprotein(a) concentrations were treated as a continuous variable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, higher plasma lipoprotein(a) concentrations were associated with faster rates of hemodynamic progression in patients with aortic stenosis. Lowering plasma lipoprotein(a) concentrations warrants further investigation in the prevention and treatment of aortic stenosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39018080/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39018080</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11255972/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">PMC11255972</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1882>10.1001/jamacardio.2024.1882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39018080</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Benoit J Arsenault</dc:creator>
<dc:creator>Krithika Loganath</dc:creator>
<dc:creator>Arnaud Girard</dc:creator>
<dc:creator>Simona Botezatu</dc:creator>
<dc:creator>Kang H Zheng</dc:creator>
<dc:creator>Evangelos Tzolos</dc:creator>
<dc:creator>Kathia Abdoun</dc:creator>
<dc:creator>Lionel Tastet</dc:creator>
<dc:creator>Romain Capoulade</dc:creator>
<dc:creator>Nancy Côté</dc:creator>
<dc:creator>Neil Craig</dc:creator>
<dc:creator>Kwan L Chan</dc:creator>
<dc:creator>James W Tam</dc:creator>
<dc:creator>Koon K Teo</dc:creator>
<dc:creator>Christian Couture</dc:creator>
<dc:creator>Marie-Annick Clavel</dc:creator>
<dc:creator>Patrick Mathieu</dc:creator>
<dc:creator>Sébastien Thériault</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis</dc:title>
<dc:identifier>pmid:39018080</dc:identifier>
<dc:identifier>pmc:PMC11255972</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1882</dc:identifier>
</item>
<item>
<title>Racial Disparities in Sports Cardiology: A Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39018059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In sports cardiology, inadequate consideration of the impact of structural racism and SDOH on racial disparities in health outcomes among athletes has resulted in potential biases in current normative standards and in the clinical approach to the cardiovascular care of athletes. An evidence-based approach to successfully address disparities requires pivoting from outdated race-based practices to a race-conscious framework to better understand and improve health care...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 17. doi: 10.1001/jamacardio.2024.1899. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Racial disparities in cardiovascular health, including sudden cardiac death (SCD), exist among both the general and athlete populations. Among competitive athletes, disparities in health outcomes potentially influenced by social determinants of health (SDOH) and structural racism remain inadequately understood. This narrative review centers on race in sports cardiology, addressing racial disparities in SCD risk, false-positive cardiac screening rates among athletes, and the prevalence of left ventricular hypertrophy, and encourages a reexamination of race-based practices in sports cardiology, such as the interpretation of screening 12-lead electrocardiogram findings.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: Drawing from an array of sources, including epidemiological data and broader medical literature, this narrative review discusses racial disparities in sports cardiology and calls for a paradigm shift in approach that encompasses 3 key principles: race-conscious awareness, clinical inclusivity, and research-driven refinement of clinical practice. These proposed principles call for a shift away from race-based assumptions towards individualized, health-focused care in sports cardiology. This shift would include fostering awareness of sociopolitical constructs, diversifying the medical team workforce, and conducting diverse, evidence-based research to better understand disparities and address inequities in sports cardiology care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In sports cardiology, inadequate consideration of the impact of structural racism and SDOH on racial disparities in health outcomes among athletes has resulted in potential biases in current normative standards and in the clinical approach to the cardiovascular care of athletes. An evidence-based approach to successfully address disparities requires pivoting from outdated race-based practices to a race-conscious framework to better understand and improve health care outcomes for diverse athletic populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39018059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39018059</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1899>10.1001/jamacardio.2024.1899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39018059</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sheela Krishnan</dc:creator>
<dc:creator>James Sawalla Guseh</dc:creator>
<dc:creator>Merije Chukumerije</dc:creator>
<dc:creator>Aubrey J Grant</dc:creator>
<dc:creator>Peter N Dean</dc:creator>
<dc:creator>Jeffrey J Hsu</dc:creator>
<dc:creator>Mustafa Husaini</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Ankit B Shah</dc:creator>
<dc:creator>Katie Stewart</dc:creator>
<dc:creator>Meagan M Wasfy</dc:creator>
<dc:creator>Quinn Capers</dc:creator>
<dc:creator>Utibe R Essien</dc:creator>
<dc:creator>Amber E Johnson</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>American College of Cardiology Sports &amp; Exercise Leadership Council</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Racial Disparities in Sports Cardiology: A Review</dc:title>
<dc:identifier>pmid:39018059</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1899</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39018040/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this long-term prospective serial CCTA imaging study, higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. These data suggest an impact of elevated Lp(a) levels on coronary atherogenesis of high-risk, inflammatory, rupture-prone plaques over the long term.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 17:e241874. doi: 10.1001/jamacardio.2024.1874. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Lipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular disease; however, long-term effects on coronary atherosclerotic plaque phenotype, high-risk plaque formation, and pericoronary adipose tissue inflammation remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the association of Lp(a) levels with long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This single-center prospective cohort study included 299 patients with suspected coronary artery disease (CAD) who underwent per-protocol repeated coronary computed tomography angiography (CCTA) imaging with an interscan interval of 10 years. Thirty-two patients were excluded because of coronary artery bypass grafting, resulting in a study population of 267 patients. Data for this study were collected from October 2008 to October 2022 and analyzed from March 2023 to March 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: The median scan interval was 10.2 years. Lp(a) was measured at follow-up using an isoform-insensitive assay. CCTA scans were analyzed with a previously validated artificial intelligence-based algorithm (atherosclerosis imaging-quantitative computed tomography).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The association between Lp(a) and change in percent plaque volumes was investigated in linear mixed-effects models adjusted for clinical risk factors. Secondary outcomes were presence of low-density plaque and presence of increased pericoronary adipose tissue attenuation at baseline and follow-up CCTA imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The 267 included patients had a mean age of 57.1 (SD, 7.3) years and 153 were male (57%). Patients with Lp(a) levels of 125 nmol/L or higher had twice as high percent atheroma volume (6.9% vs 3.0%; P = .01) compared with patients with Lp(a) levels less than 125 nmol/L. Adjusted for other risk factors, every doubling of Lp(a) resulted in an additional 0.32% (95% CI, 0.04-0.60) increment in percent atheroma volume during the 10 years of follow-up. Every doubling of Lp(a) resulted in an odds ratio of 1.23 (95% CI, 1.00-1.51) and 1.21 (95% CI, 1.01-1.45) for the presence of low-density plaque at baseline and follow-up, respectively. Patients with higher Lp(a) levels had increased pericoronary adipose tissue attenuation around both the right circumflex artery and left anterior descending at baseline and follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this long-term prospective serial CCTA imaging study, higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. These data suggest an impact of elevated Lp(a) levels on coronary atherogenesis of high-risk, inflammatory, rupture-prone plaques over the long term.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39018040/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39018040</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11255968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">PMC11255968</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1874>10.1001/jamacardio.2024.1874</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39018040</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Emilie L Gaillard</dc:creator>
<dc:creator>Shant Malkasian</dc:creator>
<dc:creator>Robin J de Groot</dc:creator>
<dc:creator>Shirin Ibrahim</dc:creator>
<dc:creator>Michiel J Bom</dc:creator>
<dc:creator>Yannick Kaiser</dc:creator>
<dc:creator>James P Earls</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>Jeffrey Kroon</dc:creator>
<dc:creator>R Nils Planken</dc:creator>
<dc:creator>Ibrahim Danad</dc:creator>
<dc:creator>Alexander R van Rosendael</dc:creator>
<dc:creator>Andrew D Choi</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>Paul Knaapen</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation</dc:title>
<dc:identifier>pmid:39018040</dc:identifier>
<dc:identifier>pmc:PMC11255968</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1874</dc:identifier>
</item>
<item>
<title>Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39016180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240719141228&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Adding cancer to the PRECISE-DAPT score identifies the majority of patients with cancer as HBR and can improve its discrimination ability without undermining its performance in patients without cancer.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 17:ehae463. doi: 10.1093/eurheartj/ehae463. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: This study assessed the impact of incorporating cancer as a predictor on performance of the PRECISE-DAPT score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A nationally linked cohort of ST-elevation myocardial infarction patients between 1 January 2005 and 31 March 2019 was derived from the UK Myocardial Ischaemia National Audit Project and the UK Hospital Episode Statistics Admitted Patient Care registries. The primary outcome was major bleeding at 1 year. A new modified score was generated by adding cancer as a binary variable to the PRECISE-DAPT score using a Cox regression model and compared its performance to the original PRECISE-DAPT score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 216 709 ST-elevation myocardial infarction patients were included, of which 4569 had cancer. The original score showed moderate accuracy (C-statistic .60), and the modified score showed modestly higher discrimination (C-statistics .64; hazard ratio 1.03, 95% confidence interval 1.03-1.04) even in patients without cancer (C-statistics .63; hazard ratio 1.03, 95% confidence interval 1.03-1.04). The net reclassification index was .07. The bleeding rates of the modified score risk categories (high, moderate, low, and very low bleeding risk) were 6.3%, 3.8%, 2.9%, and 2.2%, respectively. According to the original score, 65.5% of cancer patients were classified as high bleeding risk (HBR) and 21.6% were low or very low bleeding risk. According to the modified score, 94.0% of cancer patients were HBR, 6.0% were moderate bleeding risk, and no cancer patient was classified as low or very low bleeding risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Adding cancer to the PRECISE-DAPT score identifies the majority of patients with cancer as HBR and can improve its discrimination ability without undermining its performance in patients without cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39016180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240719141228&v=2.18.0.post9+e462414">39016180</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae463>10.1093/eurheartj/ehae463</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39016180</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mohamed Dafaalla</dc:creator>
<dc:creator>Francesco Costa</dc:creator>
<dc:creator>Evangelos Kontopantelis</dc:creator>
<dc:creator>Mario Araya</dc:creator>
<dc:creator>Tim Kinnaird</dc:creator>
<dc:creator>Antonio Micari</dc:creator>
<dc:creator>Haibo Jia</dc:creator>
<dc:creator>Gary S Mintz</dc:creator>
<dc:creator>Mamas A Mamas</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score</dc:title>
<dc:identifier>pmid:39016180</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae463</dc:identifier>
</item>





























</channel>
</rss>